Search results
Results from the WOW.Com Content Network
This variability is influenced by the number of F5 gene (chromosome 1) mutations a person has, the presence of other gene alterations related to blood clotting, and circumstantial risk factors, such as surgery, use of oral contraceptives and pregnancy. [citation needed] Symptoms of factor V Leiden include: [citation needed]
14067 Ensembl ENSG00000198734 ENSMUSG00000026579 UniProt P12259 O88783 RefSeq (mRNA) NM_000130 NM_007976 RefSeq (protein) NP_000121 NP_032002 Location (UCSC) Chr 1: 169.51 – 169.59 Mb Chr 1: 163.98 – 164.05 Mb PubMed search Wikidata View/Edit Human View/Edit Mouse Coagulation factor V (Factor V), also less commonly known as proaccelerin or labile factor, is a protein involved in ...
The minor ("type 2") thrombophilias are much more common. Factor V Leiden is present in 5% of the population of Northern European descent, but much rarer in those of Asian or African extraction. In people with thrombosis, 10% have factor V Leiden. In those who are referred for thrombophilia testing, 30–50% have the defect.
“Typically, it is not any one modality that targets these symptoms for a person, it is more often a combination of various modalities that gives the most optimal results,” says Dr. Israel.
The study, which involved 106 peri- and postmenopausal women and was presented at the Endocrine Society’s annual meeting in May, indicates women should self-monitor their vasomotor symptoms and ...
Beyond the symptoms listed in the BE-FAST mnemonic, Kamdar says some less noticeable signs of stroke seen in women include severe headache, generalized weakness, generalized fatigue, shortness of ...
Symptoms classically affect a leg and typically develop over hours or days, [20] though they can develop suddenly or over a matter of weeks. [21] The legs are primarily affected, with 4–10% of DVT occurring in the arms. [11] Despite the signs and symptoms being highly variable, [5] the typical symptoms are pain, swelling, and redness.
This page was last edited on 24 November 2003, at 09:57 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.